于雯华 Yu, Jocelyn Ph.D.

律师

圣地亚哥 + 1.858.314.1186

Dr. 于雯华 (Jocelyn) 是一位经验丰富的知识产权(IP)律师,并专注于生命科学领域。她拥有超过12年的执业经验,致力于帮助客户最大限度地保护知识产权并利用IP权利加强商业战略和交易。Jocelyn 服务的客户群涵盖位于不同发展阶段的生物技术企业以及跨国制药公司。Jocelyn的专业领域涵盖全球专利战略布局、IP尽职调查以及许可合作谈判。

Jocelyn专注于为企业量身定制IP和专利策略。她与科学团队密切合作,使专利策略布局与治疗管线的开发保持同步。她在多个领域拥有深厚的技术知识,包括免疫疗法(如单克隆抗体、多特异性抗体、T细胞衔接器)、基因和细胞疗法(如CAR-T、CRISPR)、疫苗、小分子药物、偶联疗法(如抗体药物偶联物ADC、寡核苷酸偶联物AOC、放射性核素偶联物)以及制造和递送技术(如脂质纳米颗粒LNP、腺相关病毒AAV)。她曾为行业领军企业(如BMS/Celgene、默克公司、强生公司)进行广泛的尽职调查并提供法律意见,以支持其研发、IP和商业战略,并参与过多个商业化产品的相关工作。

除了专利业务外,Jocelyn还拥有超过8年的经验,为生物技术和制药公司提供技术交易和合作关系战略咨询,包括构建、谈判和准备IP许可与合作协议。她还为客户提供协议执行后的关系管理服务,并协助调查和解决IP相关争议。Jocelyn曾代表客户参与美国与亚洲市场之间的跨境交易,客户机构包括Incyte Corporation、上海君实生物、上海济煜医药、创响生物等。

Jocelyn 担任加州生物技术协会(Biocom California)的知识产权与专利法委员会联席主席。Jocelyn同时担任南加州生物医学与制药促进协会(SABPA)的董事会成员,并兼任SABPA 的创业与合作委员会联席主席。

经验

  • Inmagene Biopharmaceuticals grants global rights to develop, manufacture, and commercialize antibody therapeutic candidatesJones Day advised Inmagene Biopharmaceuticals on granting global rights for collaborations with multiple partners to develop, manufacture, and commercialize antibody therapeutic candidates.
  • Jemincare and RAPT collaborate to develop and commercialize JYB1904Jones Day advised Shanghai Jemincare Pharmaceutical Co., LTD. (Jemincare), a subsidiary of Jiangxi Jemincare Group, a leading pharmaceutical company in China, on its exclusive license agreement with RAPT Therapeutics (Nasdaq: RAPT) for JYB1904, a clinical-stage, half-life extended anti-IgE monoclonal antibody.
  • Merck Animal Health develops global patent portfolios for various veterinary pharmaceuticals and biologics, vaccines, and other health management solutionsJones Day is representing Merck Animal Health, a division of Merck & Co., and the global animal health business of Merck, in developing global patent portfolios related to a wide variety of veterinary pharmaceuticals and biologicals, vaccines, and other health management solutions used to preserve and improve the health, well-being, and performance of animals, including companion animals, ruminants, horses, poultry, and swine.
  • VST Bio establishes global patent portfolios related to anti-syndecan-2 antibodies for the treatment of diseases related to vascular permeabilityJones Day is representing VST Bio Corp. in connection with the establishment of a global patent portfolio related to antibodies that target syndecan-2 and uses thereof in the treatment of diseases related to vascular permeability and leakage, including ischemic stroke and myocardial infarction.
  • Incyte grants rights to CMS for ruxolitnib cream in China and Southeast AsiaJones Day represented Incyte Corporation in its Collaboration and License Agreement with CMS Aesthetics Limited for the development and commercialization of ruxolitinib cream, a novel cream formulation of Incyte’s selective JAK inhibitor ruxolitinib, for the treatment of autoimmune and inflammatory dermatologic diseases in Greater China and certain countries in Southeast Asia. 
  • DNARx develops global patent portfolios for HEDGES™ gene therapy platformJones Day represents DNARx, LLC in the development and prosecution of global patent portfolios related to HEDGES™ (High-level Extended Duration Gene Express System), DNARx's proprietary non-viral gene therapy together with gene-based, highly combinatorial anti-pandemic monoclonal antibody cDNA-encoded protein delivery platform technology for the treatment of various unmet medical needs.
  • Suzhou Abogen Biosciences establishes global patent portfolios for mRNA-based vaccines and nano-delivery platform technologiesJones Day represents Suzhou Abogen Biosciences Co., Ltd. in the establishment and prosecution of global patent portfolios related to mRNA-based vaccines for infectious diseases, such as COVID-19, as well as nano-delivery platform technologies.
  • AbbVie acquires Mitokinin, Inc.Jones Day advised AbbVie Inc. in its exclusive right to acquire Mitokinin, Inc., a biotechnology company developing PINK1-targeted therapeutics for the treatment of neurodegenerative diseases, following completion of IND enabling studies on Mitokinin's lead PINK1 compound.
  • Burning Rock establishes global patent portfolio for NGS-related diagnostics and precision oncologyJones Day represents Burning Rock in the development and prosecution of global patent portfolios related to next generation sequencing (NGS) technology for diagnostic and of precision oncology.
  • Junshi and Lilly to develop and commercialize antibodies for prevention and treatment of COVID-19 coronavirusJones Day represented Shanghai Junshi Biosciences Co., Ltd. in its strategic collaboration and license agreement with Eli Lilly and Company for the development, manufacturing, and commercialization of two antibodies for the prevention and treatment of the COVID-19 SARS-CoV-2 novel coronavirus.
  • Celgene acquired by Bristol-Myers Squibb for approximately $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
  • VersaPeutics collaborates with UCSD in developing pharmaceutical candidates for treatment of neurological and oncological diseasesJones Day represented VersaPeutics, Inc. in its strategic collaboration and license agreement with University of California San Diego ("UCSD") for the development of pre-clinical stage therapeutic candidates for the treatment of certain neurological and oncological diseases.
  • Sanofi and Denali Therapeutics collaborate to develop treatments for neurological and inflammatory diseasesJones Day represented Sanofi in its strategic collaboration and license agreement with Denali Therapeutics for the development, manufacturing, and commercialization of many pre-clinical and clinical candidates for treatment of certain neurological and systemic inflammatory diseases, including those known to target RIPK1, such as MS, Alzheimer's Disease and ALS, and rheumatoid arthritis.
  • Celgene acquires Juno Therapeutics for $9 billionOn behalf of Celgene Corporation, Jones Day conducted a large-scale intellectual property due diligence review and evaluation of matters related to its definitive merger agreement and acquisition of Juno Therapeutics for approximately $9 billion, including Juno’s technology related to CAR-T and TCR cellular immunotherapeutics for use in oncology and other indications.
  • Celgene develops global patent portfolio for agonistic anti-PD1 antibody therapeuticsJones Day represents Celgene Corporation in the establishment of a global patent portfolio related to agonistic anti-PD1 therapeutic antibodies.
    • October 27, 2022
      Practical Considerations in Continuation/Divisional Patent Application Practice
    • September 28, 2022
      Key topics for negotiation in Cross-the-Border Out-Licensing of Pharmaceutical Assets and Case Studies (Presentation in Mandarin)
    • January 25, 2022
      Key Topics For Negotiation in Life Science Licensing Transactions
    • November 7, 2018
      Licensing Fundamentals for Business Executives and Startups